Bangalore?

Bangalore, a city in southern India on the Deccan plateau, transformed in the mid-twentieth century from a regional administrative centre into the world's largest producer of animal serum for serum therapy. The city's evolution was direct consequence of the absence of reliable systemic azo drugs — once the allied invasions of 1943 revealed that septicaemia could not be treated by chemical means, India's abundant veterinary resources and tropical disease expertise made it the natural site for scaling serum production to meet global demand.

The city hosted the South India Serum Institute from its founding in 1954, initially a government facility under the Ministry of Health, and expanded rapidly as serum therapy became recognized in the 1970s as the primary alternative to chemical antibacterials. By 1985, the city's five major serum producers collectively maintained hyperimmunized herds of over 40,000 animals — horses, goats, and cattle whose blood was harvested and processed into neutralizing sera for diphtheria antitoxin, meningitis treatment, and experimental endocarditis serums. Production records held at the Ministry of Health Archives in New Delhi show a rise from 12 million units of antitoxin in 1960 to nearly 800 million units in 2000, with Bangalore accounting for roughly 65 percent of that output.

The city's suitability for the work rested partly on climate. Tropical conditions allowed year-round animal breeding, and the local veterinary colleges could supply trained handlers and researchers. More fundamentally, Bangalore had escaped the heavy bombing of the Second World War and remained administratively intact when the Bacillary Congress of Geneva in 1952 standardized serum therapy as the coordinated response to untreatable infection. The Geneva Sanitary Bureau, established to oversee asepsis maximalism protocols, appointed a permanent liaison office in Bangalore in 1956, and the city became the de facto international hub for serum distribution and quality control.

The South India Serum Institute's master plans, archived at the institute itself, show that from 1960 onward the facility was designed around biological containment and seasonal animal production. The hyperimmunization protocols developed there under director Rajesh Sharma became the international standard — the details of which animal species, dosing schedules, and toxoid preparations produced the highest-titre sera were published in the Quarterly Journal of Serum Pharmacology and adopted by producers in Europe and North America. The institute's archival correspondence with Dorothy Umezaki during her visits in 1975 and 1978 documents the early clinical trials of the Halloway-Umezaki method, which relied heavily on Bangalore-produced antitoxin stocks.

The social cost was substantial. By 1975, roughly 12 percent of Bangalore's industrial workforce was employed in serum production, handling and bleeding animals under strict asepsis maximalism protocols. Occupational injury rates in the serum industry were consistently higher than in manufacturing or textile work, though the bureau's published figures, issued biennially from 1960 onward, attributed these to workers' failure to follow containment procedures rather than to the inherent risks of large-scale animal blood handling. The precise count of occupational infections remains disputed — the institute's own records show 187 cases of animal-related infection from 1954 to 1990, while independent investigators using epidemiological records from municipal hospitals documented over 300 cases in the same period.

By the 1980s Bangalore's role was being shaped by the International Serum Registry, established in 1975 to standardize treatment outcomes and manage biological resource allocation. The registry's headquarters in Geneva maintained detailed records of each batch of serum produced in Bangalore, testing protocols and efficacy data that made the city's output visible to clinicians worldwide. This transparency transformed Bangalore into something between an industrial centre and a research station — the serum it produced was studied as intensively as manufactured, and every batch was tracked epidemiologically in the hands of hospitals across three continents.

The city's cultural identity shifted accordingly. Serum production work carried the social weight of infection control — necessary but tinged with the stigma of disease management that in the Long Sepsis attached to any profession dealing directly with pathogenic material. Butchers, morticians, and serum workers occupied a similar social rank, respected for essential work but socially cordoned off in the way that plague handlers had been in earlier centuries. This was explicit in housing records from the municipal administration: workers in serum production received housing stipends that reflected hazard pay, but were not permitted to live in the same quarters as civil servants or industrial workers in less contamination-intensive trades.

By the early twenty-first century, Bangalore's position had begun to shift. Advances in recombinant antibody technology in wealthy nations, and the growing use of synthetic serum substitutes, reduced demand for animal-derived sera. The South India Serum Institute remained in operation but contracted; by 2010 its workforce had fallen to roughly half its peak. The city retained its expertise and its hyperimmunized herds as a global reserve against outbreaks, but the era in which Bangalore was the irreplaceable centre of serum production had passed.